FDA OKs Interpore's posterior cervical spine implant
This article was originally published in Clinica
Executive Summary
Interpore Cross International has gained FDA go-ahead to sell its posterior cervical spine implant, a product which the firm believes will tap into a US market worth around $40m annually.